Food and Drug Regulations (C.R.C., c. 870)

Regulations are current to 2013-06-10 and last amended on 2013-05-31. Previous Versions

 Both the inner and the outer labels of a drug that carry a recommended single or daily dosage or a statement of concentration in excess of the limits provided by section C.01.021 shall carry a caution that the product is to be used only on the advice of a physician.

 The provisions of section C.01.025 do not apply to

  • (a) a drug sold on prescription, or

  • (b) the inner label of a single-dose container.

  •  (1) Where a person advertises to the general public a drug for human use, the person shall not make any representation other than with respect to the brand name, proper name, common name, price and quantity of the drug if it

    • (a) contains a drug set out in the table to section C.01.021; and

    • (b) carries on its label

      • (i) a statement of the recommended single or daily adult dosage that results in a single or daily adult dosage of the drug referred to in paragraph (a) in excess of the maximum dosage set out in the table to section C.01.021 for that drug, or

      • (ii) a statement that shows a concentration of the drug referred to in paragraph (a) in excess of the maximum limit set out in the table to section C.01.021 for that drug.

  • (2) Subsection (1) does not apply to products containing

    • (a) acetaminophen;

    • (b) acetylsalicylic acid;

    • (c) choline salicylate;

    • (d) magnesium salicylate; or

    • (e) sodium salicylate.

  • (3) [Repealed, SOR/94-409, s. 1]

  • (4) Where a person advertises to the general public a drug for human use that contains acetylsalicylic acid, the person shall not make any representation with respect to its administration to or use by children or teenagers.

  • SOR/81-358, s. 1;
  • SOR/84-145, s. 3;
  • SOR/85-715, s. 4(F);
  • SOR/85-966, s. 3;
  • SOR/93-202, s. 5;
  • SOR/93-411, s. 1;
  • SOR/94-409, s. 1.

Cautionary Statements and Child Resistant Packages

  •  (1) Subject to subsection (2), the inner and outer labels of a drug that contains

    • (a) acetylsalicylic acid or any of its salts or derivatives, salicylic acid or a salt thereof, or salicylamide, where the drug is recommended for children, shall carry a cautionary statement to the effect that the drug should not be administered to a child under two years of age except on the advice of a physician;

    • (b) boric acid or sodium borate as a medicinal ingredient shall carry a cautionary statement to the effect that the drug should not be administered to a child under three years of age;

    • (c) hyoscine (scopolamine) or a salt thereof shall carry a cautionary statement to the effect that the drug should not be used by persons suffering from glaucoma or where it causes blurring of the vision or pressure pain within the eye;

    • (d) phenacetin, either singly or in combination with other drugs, shall carry the following cautionary statement:

      “CAUTION: May be injurious if taken in large doses or for a long time. Do not exceed the recommended dose without consulting a physician.”; or

    • (e) acetylsalicylic acid for internal use shall carry a cautionary statement to the effect that the drug should not be administered to or used by children or teenagers who have chicken pox or manifest flu symptoms before a physician or pharmacist is consulted about Reye’s syndrome, which statement shall also refer to the fact that Reye’s syndrome is a rare and serious illness.

  • (2) Subsection (1) does not apply to a drug that is

    • (a) intended for parenteral use only;

    • (b) dispensed pursuant to a prescription; or

    • (c) required to be sold on prescription pursuant to these Regulations or pursuant to the Narcotic Control Regulations.

  • SOR/86-93, s. 2;
  • SOR/88-323, s. 2(F);
  • SOR/93-411, s. 2.